InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the complete record of transactions filed by JONAS JEFFREY M, Director. Insider active across 2 companies, notably Sage Therapeutics, Inc.. Cumulatively, 18 reports have been published. Split: 1 buy · 0 sell. Activity tracked since 15 June 2021. The latest transaction was disclosed on 18 March 2024 (Disposition). Regulator: SEC (Form 4). All data is openly available.
Declarations18 total
990 shares@ US$330.0052.1% of flowCommon StockSEC:0001140361-24-013926:0
10,000 shares0Common StockSEC:0001562180-23-007980:0
13,809 shares@ US$7.2716.1% of flowCommon StockSEC:0000950170-23-046439:0
13,810 shares@ US$7.2715.8% of flowCommon StockSEC:0000950170-23-037379:0
13,810 shares@ US$7.2716.0% of flowCommon StockSEC:0000950170-23-031688:0
990 shares0Common StockSEC:0000950170-23-029411:0
11,643 shares@ US$0.455.5% of flowCommon StockSEC:0001562180-23-001257:0
5,100 shares0Common StockSEC:0001562180-23-001083:0
2,501 shares@ US$28.6376.0% of flowCommon StockSEC:0001562180-23-000234:0
30,944 shares@ US$0.4580.7% of flowCommon StockSEC:0001562180-22-003565:0
4,000 shares@ US$0.459.7% of flowCommon StockSEC:0001562180-22-001626:0
4,000 shares@ US$0.45100.0% of flowCommon StockSEC:0001562180-22-001626
10,000 shares0Common StockSEC:0001562180-21-006597:0
10,000 shares0Common StockSEC:0001562180-21-006597
10,000 shares0Common StockSEC:0001562180-21-004340
10,000 shares0Common StockSEC:0001562180-21-004340:0
226 sharesCommon StockSEC:0001562180-16-001290:0
Ideal exit: 26 Sept 2016 (T+270)
20,000 sharesCommon StockSEC:0001562180-16-001290:1
18 of 18 declarations
About JONAS JEFFREY M
Jeffrey M. Jonas is the Chief Innovation Officer and a Board Member at Sage Therapeutics, Inc. He is responsible for leading innovation and research initiatives. His expertise is essential for developing new therapeutic solutions.
